Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01579422 · ClinicalTrials.gov registry record · Phase 1

Social Cognitive Training for Psychosis: Treatment Development

A Phase 1 study of Schizophrenia and Psychosis, sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
77
Enrollment target
1
Study location

NCT01579422: Completed Phase 1 study of Schizophrenia and Psychosis, sponsored by Yale University.

NCT01579422 is a Phase 1 study of Schizophrenia and Psychosis that has completed, run by Yale University. The registered enrollment target is 77 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01579422, a Phase 1 study of Schizophrenia and Psychosis, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
77 participants
Enrollment target
1
Study location

Study Summary

The primary aim of this proposal is to develop, refine, manualize and assess the feasibility and preliminary efficacy of a brief, narrowly-focused social cognitive intervention for individuals with psychosis. The intervention will focus on helping individuals interpret social situations, specifically the intentions and feelings of others. Study methods include preliminary treatment and manual development based on series of uncontrolled cases, manual refinement, and a small feasibility/efficacy trial of the newly developed intervention.

Primary Outcome

AIHQ Eyes Task Hinting Task IPSAQ

Conditions Studied

Schizophrenia Psychosis

Interventions

  • BEHAVIORAL social cognitive training

Study Locations (1)

Connecticut

  • VA Connecticut Healthcare System - West Haven

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2012-05
Est. Completion 2015-12
Phase Phase 1
Yale University

1,492 total trials

What the finished NCT01579422 record still lists

NCT01579422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower).

The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which social cognitive training is the first listed.

NCT01579422 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT01579422 about?

NCT01579422 is a clinical study titled "Social Cognitive Training for Psychosis: Treatment Development". The primary aim of this proposal is to develop, refine, manualize and assess the feasibility and preliminary efficacy of a brief, narrowly-focused social cognitive intervention for individuals with psychosis. The intervention will focus on helping individuals interpret social situations, specificall...

What is the current status of trial NCT01579422?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2012-05. Estimated completion is 2015-12.

What conditions does trial NCT01579422 study?

This clinical trial studies the following conditions: Schizophrenia, Psychosis.

What interventions are being tested in trial NCT01579422?

The interventions under investigation include: social cognitive training (BEHAVIORAL).

Who is sponsoring clinical trial NCT01579422?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01579422 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01579422's enrollment target sits among peer trials

77 167th of 315 higher than 148 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02127398 · 77 participants · Phase 2

    Stool Transplants to Treat Refractory Clostridium Difficile Colitis

  • NCT04159103 · 77 participants · Phase 1

    Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

  • NCT04683003 · 77 participants · Phase 3

    A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

  • NCT05004116 · 77 participants · Phase 1

    A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01579422, the US trial registry maintained by the National Library of Medicine. NCT01579422 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.